Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px
Document › Details

BeiGene (Beijing) Co., Ltd.. (9/2/14). "Press Release: Boehringer Ingelheim and BeiGene Announce Strategic Supply and Manufacturing Agreement in China". Shanghai & Beijing.

Region Region China
Organisations Organisation BeiGene (Beijing) Co., Ltd.
  Group BeiGene (Group)
  Organisation 2 Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd.
  Group Boehringer Ingelheim (Group)
Products Product contract manufacturing (biologicals)
  Product 2 antibody cancer drug
Index term Index term BeiGene–Boehringer: biopharmaceuticals, 201409– strategic supply + manufacturing agreem for biopharmaceuticals using mammalian cell culture technology
Persons Person Oyler, John V. (BeiGene 201305 CEO & Co-Founder)
  Person 2 von Baumbach, Hubertus (Boehringer Ingelheim 201609 Chairman before Managing Director Finance)

Boehringer Ingelheim and BeiGene (Beijing), Co., Ltd., today announced that the two companies have entered into a strategic agreement to manufacture biopharmaceuticals in China for BeiGene's clinical oncology trials. The new Boehringer Ingelheim manufacturing site in Zhangjiang Hi-Tech Park, Shanghai is the first facility established by a leading international biopharmaceuticals manufacturer in China utilizing mammalian cell culture technology.

"We are very pleased to announce this significant partnership with industry leader Boehringer Ingelheim BioXcellence™, and believe that entering into this agreement is a key milestone to advancing our product candidates through the clinic," commented John V. Oyler, CEO of BeiGene. "We remain focused on our goal of developing innovative therapeutics to treat the unmet medical needs of cancer patients both in China and globally. We are confident that Boehringer Ingelheim's quality facilities and clinical manufacturing capabilities will be critical to helping us achieve these goals while meeting China and global requirements for quality and regulatory compliance as our pipeline continues to rapidly progress in the years ahead."

Hubertus von Baumbach, member of the Boehringer Ingelheim Board of Managing Directors at Boehringer Ingelheim,commented: "We are excited to enter into this important agreement with the growing biopharmaceutical company BeiGene. Boehringer Ingelheim is a leading player in developing and manufacturing biopharmaceuticals. By bringing our experience to China, we are able to support more Chinese biopharmaceutical companies in developing and manufacturing biomedicines thus providing more medication of high quality to Chinese patients."

"Biopharmaceuticals is one of the key pillars driving our business in China," added David Preston, Chairman and CEO of Boehringer Ingelheim T.C.M. region. "The co-operation with BeiGene is a landmark development for us. With the support from Shanghai city level and Pudong district governments, we are able to join hands to create and fully utilize the world-class facility in Zhangjiang."

About BeiGene (Beijing), Co., Ltd.

BeiGene is an innovative Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a novel translational research platform that leverages our strong internal oncology biology expertise with unique access to a large number of patient-derived tumor biopsies. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collaborator with BeiGene (Beijing), Co. Ltd. For more information, please visit our website at

BeiGene Media/Investor Contact:
Jesse Baumgartner

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its brand Boehringer Ingelheim BioXcellence™. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience - the company has brought more than 20 biopharmaceutical products to market.
Boehringer Ingelheim China Boehringer Ingelheim's history in China dates back to 1994. Headquartered in Shanghai, Boehringer Ingelheim China has 3,300 employees nationwide with key business pillars covering prescription medicine, consumer healthcare, animal health, biopharmaceuticals, manufacturing and R&D.

The company spares no effort in bringing innovative products to the Chinese market. In recent years, Boehringer Ingelheim China has achieved successive growth outperforming the market average. Our vision is to become the premier multinational pharmaceutical company in China.

Media Contact:
May Yin
021-52880000 ext.5118

Record changed: 2019-06-09


Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for BeiGene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top